Amneal Receives U.S. FDA Complete Response Letter for IPX203

BRIDGEWATER, N.J.–(BUSINESS WIRE) July 03, 2023 –Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug…Original Article